Vos, Joris L. http://orcid.org/0000-0002-8318-5455
Elbers, Joris B. W.
Krijgsman, Oscar
Traets, Joleen J. H.
Qiao, Xiaohang http://orcid.org/0000-0002-8690-4179
van der Leun, Anne M. http://orcid.org/0000-0003-1718-2093
Lubeck, Yoni
Seignette, Iris M.
Smit, Laura A.
Willems, Stefan M.
van den Brekel, Michiel W. M. http://orcid.org/0000-0002-6338-6743
Dirven, Richard
Baris Karakullukcu, M.
Karssemakers, Luc
Klop, W. Martin C.
Lohuis, Peter J. F. M.
Schreuder, Willem H.
Smeele, Ludi E.
van der Velden, Lilly-Ann
Bing Tan, I.
Onderwater, Suzanne
Jasperse, Bas
Vogel, Wouter V.
Al-Mamgani, Abrahim
Keijser, Astrid
van der Noort, Vincent
Broeks, Annegien
Hooijberg, Erik http://orcid.org/0000-0002-4482-2191
Peeper, Daniel S. http://orcid.org/0000-0003-1293-3177
Schumacher, Ton N. http://orcid.org/0000-0003-0517-8804
Blank, Christian U. http://orcid.org/0000-0002-7945-5846
de Boer, Jan Paul
Haanen, John B. A. G. http://orcid.org/0000-0001-5884-7704
Zuur, Charlotte L.
Article History
Received: 18 February 2021
Accepted: 4 October 2021
First Online: 22 December 2021
Competing interests
: J.L.V., J.B.W.E., J.J.H.T., X.Q., A.vd.L., Y.L., I.S., L.S., S.O., B.J., W.V.V., A.A.M., V.vd.N., A.K., E.H., A.B., R.D., L.K., M.B.K., P.J.F.M.L., W.H.S., W.M.C.K., L.vd.V., and I.B.T. declare no competing interests. C.L.Z. reports receiving institutional research financial support from BMS to fund the present trial. M.W.M.vd.B. reports, outside the submitted work, institutional research funding from ATOS Medical. S.M.W. reports, all outside the submitted work: institutional research funding from Roche, Pfizer, MSD, Bayer, Amgen, BMS, AstraZeneca, Lilly and Nextcure. O.K. is employed at Neogene Therapeutics B.V., though at time of analysis and writing his employment was at the NKI. O.K. further reports, outside the submitted work, a pending patent application (title: “Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof”, number: WO2020005068A8). D.S.P. reports, all outside the submitted work, a pending patent application (title: “Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof”, number: WO2020005068A8) and a role as co-founder, shareholder and advisor of Immagene. J.P.d.B. reports, all outside the submitted work: institutional research funding from Merck KGaA; institutional honoraria for an advisory role for MSD. T.N.M.S. reports, all outside the submitted work: advisory roles for Adaptive Biotechnologies, AIMM Therapeutics, Allogene Therapeutics, Merus, Neogene Therapeutics, Neon Therapeutics and Scenic Biotech; research support from Merck KGaA; stockholdership of AIMM Therapeutics, Allogene Therapeutics, Merus, BioNTech, Neogene Therapeutics, and Scenic Biotech. C.U.B. reports, all outside the submitted work: institutional research funding from BMS, Novartis and Nanostring; institutional honoraria for advisory roles for BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, Genmab and Pierre Fabre; personal honoraria for an advisory role for Third Rock Ventures; stock ownership of Uniti Cars and Immagene. J.B.A.G.H. reports, all outside the submitted work: institutional honoraria for advisory roles for AIMM, Amgen, BioNTech, BMS, GSK, Ipsen, MSD, Merck Serono, Molecular Partners, Neogene Therapeutics, Novartis, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures, Vaximm; stock option ownership of Neogene Therapeutics; Institutional research funding from Amgen, BioNTech, BMS, MSD, Novartis.